Finally, another menin-KMT2A inhibitor, Kura Oncology (KO)-539, has been shown to inhibit leukemia growth and prolong survival in KMT2A-rearranged cell lines and in vivo models, earning the FDA Orphan Drug Designation [51]. Here, MEN1 is linked to leukemia.